key: cord-1034853-d0r09lj8 authors: Azh, Nima; Barzkar, Farzaneh; Motamed‐Gorji, Nogol; Pourvali‐Talatappeh, Parmida; Moradi, Yousef; Vesal Azad, Roya; Ranjbar, Mitra; Baradaran, Hamid Reza title: Nonsteroidal anti‐inflammatory drugs in acute viral respiratory tract infections: An updated systematic review date: 2022-02-26 journal: Pharmacol Res Perspect DOI: 10.1002/prp2.925 sha: 8659d6fadfdf102f3df4ae40e135839d3e9226a2 doc_id: 1034853 cord_uid: d0r09lj8 In this systematic review, we aimed to assess the efficacy and safety of nonsteroidal anti‐inflammatory drugs (NSAIDs) in treating respiratory tract infections in adults and children. PubMed, Scopus, Web of Science, Cochrane, and Embase databases were searched. A total of 34 randomized clinical trials were included in this systematic review. We assessed the risk of bias of all included studies using the Cochrane tool for risk of bias assessment. The evidence on ibuprofen, naproxen, aspirin, diclofenac, and other NSAIDs were rated for degree of uncertainty for each of the study outcomes and summarized using the grading of recommendations assessment, development, and evaluation (GRADE) approach. Our findings suggest that high‐quality evidence supports the use of NSAIDs to reduce fever in both adults and children. However, the evidence was uncertain for the use of NSAIDs to reduce cough. Most studies showed that NSAIDs significantly relieved sore throat. The evidence for mortality and oxygenation is limited. Regarding the adverse events, gastrointestinal discomfort was more frequently reported in children. For adults, our overall certainty in effect estimates was low and the increase in gastrointestinal adverse events was not clinically significant. In conclusion, NSAIDs seem to be beneficial in the outpatient management of fever and sore throat in adults and children. Although the evidence does not support their use to decrease mortality nor improve oxygenation in inpatient settings, the use of NSAIDs did not increase the rate of death or the need for ventilation in patients with respiratory tract infections. Further studies with a robust methodology and larger sample sizes are recommended. Appendices 2-6 present the risk of bias of individual studies for each of the NSAIDs. The overall risk of bias for ibuprofen and diclofenac studies was low. In the naproxen group, the risk of bias was unclear for 3 studies and low for 1 study. 13 In aspirin studies, only 2 out of 9 studies provided details about blinding of outcome assessment, therefore, the risk of bias due to inadequate blinding of outcome assessment is unclear. The overall risk of bias in the aspirin studies was unclear to low (Appendices 2-6). Below, we present an overview of the effects of each of the NSAIDs on our outcomes: fever, cough, sore throat, respiratory distress, hospital stay, and adverse events. Twelve studies that assessed the efficacy of Ibuprofen on signs and symptoms of ARTI were finally included in our systematic review. Tables 2 and 3 present the results of each of these studies. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Fever Four studies investigated the effectiveness of ibuprofen for fever control in children in the outpatient setting. Kim et al 19 compared ibuprofen with dexibuprofen and found that ibuprofen reduced fever by 1.38˚C ± 0.84˚C and was not significantly different from dexibuprofen. Yoon et al 25 compared ibuprofen with dexibuprofen for fever reduction during a 6-hour period and found that ibuprofen reduced fever by 0.9˚C ± 0.9˚C and was not significantly different from dexibuprofen. Hay et al 18 Four studies investigated ibuprofen effects on the sore throat in adults. Two out of 4 studies used ibuprofen as an add-on to other drugs. Gwaltney 17 Hay et al 18 investigated the clinical recovery of outpatient children from the disease on the second and fifth day; 33% and 40% of patients in ibuprofen and paracetamol groups recovered, respectively. We did not find any study to investigate LOS and ibuprofen in adults. Only 1 study assessed mortality as an outcome with the use of ibuprofen. Bernard et al 14 reported a nonsignificant small reduction in mortality. Four studies investigated the efficacy of naproxen in ARTIs, and the results are presented in Table 4 . 13, 26-28 Sperber et al 28 examined the effect of naproxen on subjective chilliness score (0-4) and the presence of fever on individuals inoculated with rhinovirus. They reported that naproxen effectively prevented fever (RR, 0.14; 95% CI, 0.03 to 0.59) and improved chilliness scores in a 4-day trial. Sperber et al 28 Sore throat was investigated in three studies. However, because of inadequate reporting, we were unable to determine effect estimates. In the Sperber et al trial, 28 naproxen did not significantly relieve sore throat (MD, 0.5; 95% CI, −0.93 to 1.9). Hung et al 13 used a combination of naproxen, clarithromycin, and oseltamivir in patients with influenza compared with oseltamivir alone. Patients who received the drug combination were less likely to require ventilator support (RR, 0.53; 95%CI, 0.33-0.83). Patients who received clarithromycin and naproxen as an add-on to oseltamivir in the Hung et al trial 13 Three studies investigated the efficacy of diclofenac in ARTIs. [29] [30] [31] Fever Two studies investigated fever control using diclofenac. In the study Table 5 . Overall, diclofenac effectively reduced fever in adults with ARTI symptoms. No studies in the diclofenac group investigated cough-related outcomes. Two studies investigated the effectiveness of diclofenac in the treatment of sore throat. Bettini et al 29 adults with influenza-like symptoms. No studies involving diclofenac investigated these outcomes. Three studies investigated GI outcomes. Weckx et al 31 Nine studies investigated the efficacy of aspirin in ARTIs and the results are presented in Tables 6 and 7 Abbreviations: CI, Confidence interval; RR, Risk ratio. *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). Three articles assessed fever reduction for aspirin and all showed a significant reduction of fever. Six studies assessed the effects of aspirin on sore throat using a variety of measures and tools. 32 Although Penicillin is used in both groups, the Ibuprofen group had a significant reduction in sore throat. Ibuprofen likely results in a large decrease in pediatric sore Throat. No studies investigated the efficacy of viral ARDS in the pediatric population. High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Abbreviations: CI, Confidence interval; RR, Risk ratio. *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). reported a moderate reduction in pain, whereas the rest of the studies did not show a significant difference with placebo. The study by Kor et al in 2016, 38 assessed the effects of aspirin compared with placebo in 390 adult patients at risk of ARDS. The study did not show a significant reduction in respiratory distress, ICU admission, ventilation support, or mortality with aspirin. Seven studies investigated GI adverse events in adults. 32, [34] [35] [36] [38] [39] [40] Kor et al 38 reported that gastrointestinal bleeding was not significantly related to a 7-day intravenous use of low-dose aspirin. These 7 studies showed differing results with great imprecision. We pooled six studies for the meta-analysis that used 1000 mg aspirin for up to 3 days on adult patients in the outpatient setting. High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect Explanations: a. fever in this study is not reported as mean temperature. A 4-score subjective scale and consecutive dichotomous temperature measurement are reported; b. The total number of participants is below 100; c. Surrogate outcomes are used for ARDS. a co-intervention of clarithromycin was used along with naproxen; d. A co-intervention of clarithromycin was used along with naproxen and e. Effect estimates in 3 studies demonstrate a wide confidence interval; this could be due to a sample size of less than 100 patients per trial. Also, effect estimates are not consistent in larger trials. Abbreviations: CI, Confidence interval; MD, Mean difference; RR, Risk ratio. *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 0% The findings of our review provide a comprehensive evidence profile on the use of NSAIDs in ARTIs. Our results have been presented across different settings and populations to ensure convenience for practical reference by clinicians. Our review suggests that the current evidence supports the use of most NSAIDs with high-certainty in fever control and with moderate certainty for sore throat. However, for ARDS-related outcomes, mortality, duration, and course of the disease, the certainty of the evidence are low. Our findings confirm that ibuprofen is an effective antipyretic in adults and children and may start acting in a shorter interval after administration compared to paracetamol. However, the evidence does not support that it can reduce fever more effectively than paracetamol. The effects of ibuprofen on cough differed substantially across trials; Probably because the pathophysiological pathways that generate cough are complicated and diverse, and ibuprofen affects them differently. Older studies suggested the use of ibuprofen for cough, but newer and higher-quality evidence does not support its prescription for the sole purpose of relieving sore throat. The evidence supports the use of naproxen for fever in adults, but its use for cough, sore throat, and more severe adverse outcomes like hospitalization, ARDS, and mortality is not supported by evidence. Naproxen prescription in children may be associated with an increased risk of gastrointestinal adverse events. Diclofenac is also effective for fever reduction and may have a longer duration of effect compared with aspirin. However, its use for Diclofenac likely does not increase GI upset. High certainty: We are very confident that the true effect lies close to that of the estimate of the effect We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Abbreviations: CI, Confidence interval. *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). cough and sore throat cannot be suggested based on current evidence. Diclofenac has shown more common gastrointestinal adverse effects compared with celecoxib, and less common compared with aspirin. However, our confidence in these findings is low because of the low event rates in the underlying studies. While the antipyretic effects of aspirin are confirmed in our systematic review, the evidence is uncertain regarding its precise effects on cough and sore throat and studies have conflicting results. It can also cause a small increase in the rate of gastrointestinal adverse effects. Abbreviations: CI, Confidence interval; RR, Risk ratio. *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). the safety of NSAIDs for usage in LRTIs, which examined mortality and the need for ventilation support. Their review that mainly consists of observational studies suggests a decline in mortality. In contrast, our review from 3 RCTs suggests no effect in either mortality or ventilator support for low-dose aspirin. Salah et al 47 in a recent meta-analysis of aspirin efficacy in Covid-19 also reported that aspirin did not affect mortality. Our findings suggest that ibuprofen may reduce mortality, however, our confidence in current evidence is low. Vaja et al 6 NSAIDs effectively reduced pain in URTIs. Our results for diclofenac strongly suggest a large reduction in sore throat pain; however, the evidence for ibuprofen and naproxen is not as certain and shows a smaller magnitude of effect. Also, the evidence with moderate certainty shows that low-dose aspirin did not affect sore throat pain. In a meta-analysis of 2 RCTs, Kim Explanations: a. lacking information on allocation and randomization, also the intervention was not blinded to participants nor the examiners; b. blinding, randomization and concealment not explained and c. very small sample sizes. Abbreviations: CI, Confidence interval; MD, Mean difference. *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). The wide scope of this review and use of nonhomogeneous variables by included studies prevented pooling of the data and meta-analysis. The results of a systematic review are limited by the quality of included studies. Some of the included studies had significant methodological flaws, which can decrease our confidence in the results of this systematic review. Particularly, small sample sizes and low event rates were key concerns in many of the included studies. RCTs that exclusively investigate the efficacy of naproxen, diclofenac, and celecoxib in viral respiratory infections are limited, and thus we need further robust studies to reach a consensus on their efficacy. In conclusion, NSAIDs seem to be beneficial in the outpatient management of fever and sore throat in adults and children. However, they do not seem to decrease mortality or improve oxygenation in inpatient settings. Further RCTs with robust methodology and a larger sample size are recommended. Ethics code: IR.IUMS.FMD.REC.1399.507. None. The authors declare no conflict of interest. ww.google.com%252F. The data that support the findings of this study are openly avail- Viral respiratory infections. Hunter's tropical medicine and emerging Pathophysiology of clinical symptoms in acute viral respiratory tract infections Non-steroidal anti-inflammatory drugs for the common cold Is use of ibuprofen safe in children with signs and symptoms of lower respiratory tract infection? Safety of ibuprofen in patients with COVID-19: causal or confounded? The COVID-19 ibuprofen controversy: a systematic review of NSAIDs in adult acute lower respiratory tract infections The PRISMA 2020 statement: an updated guideline for reporting systematic reviews GetData Graph Digitizer is a program for digitizing graphs and plots. It is often necessary to obtain original (x,y) data from graphs, e.g. from scanned scientific plots, when data values are not available. GetData Graph Digitizer allows to easily get the numbers in such cases Cochrane Handbook for Systematic Reviews of Interventions Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments Available from: http://guide lined evelo pment.org/handbook 12. Evidence Prime I. GRADEpro GDT. GRADEpro Guideline Development Tool Efficacy of clarithromycinnaproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled. Phase IIb/III Trial The effects of ibuprofen on the physiology and survival of patients with sepsis Randomized, double-blind, multicenter, controlled trial of ibuprofen versus paracetamol (paracetamol) and placebo for treatment of symptoms of tonsillitis and pharyngitis in children Pain relief of sore throat with a new anti-inflammatory throat lozenge, ibuprofen 25 mg: a randomised, double-blind, placebo-controlled, international phase III study Combined antiviral-antimediator treatment for the common cold Paracetamol and ibuprofen for the treatment of fever in children: the PITCH randomised controlled trial Dexibuprofen for fever in children with upper respiratory tract infection Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial Effectiveness of antiinflammatory treatment versus antibiotic therapy and placebo for patients with non-complicated acute bronchitis with purulent sputum. The BAAP Study protocol Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds Assessment of the efficacy and safety of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections The therapeutic effectiveness of ibuprofen on the symptoms of naturally acquired common colds The effects and safety of dexibuprofen compared with ibuprofen in febrile children caused by upper respiratory tract infection Combined antiviral and antimediator treatment of rhinovirus colds Evaluation of the efficacy and safety of nimesulide and naproxen in the symptomatic treatment of upper respiratory tract infections in children. A comparative blind study Effects of naproxen on experimental rhinovirus colds. A randomized, double-blind, controlled trial Diclofenac sodium versus acetylsalicylic acid: a randomized study in febrile patients A multicenter, randomized, double-blind, double-dummy, placebo-and activecontrolled, parallel-group comparison of diclofenac-K and ibuprofen for the treatment of adults with influenza-like symptoms Efficacy of celecoxib in treating symptoms of viral pharyngitis: a double-blind, randomized study of celecoxib versus diclofenac Aspirin compared with paracetamol in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebocontrolled, parallel-group, single-dose, 6-hour dose-ranging study Doubleblind evaluation of nimesulide vs lysine-aspirin in the treatment of paediatric acute respiratory tract infections Flurbiprofen versus ASA in influenza symptomatology: a double-blind study Effects of acetylsalicylic acid on sore throat pain and other pain symptoms associated with acute upper respiratory tract infection Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection Comparative evaluation of antipyretic activity of ibuprofen and aspirin in children with pyrexia of varied aetiology Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS-A randomized clinical trial Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold Efficacy of disintegrating aspirin in two different models for acute mild-to-moderate pain: sore throat pain and dental pain A double-blind study of zaltoprofen for the treatment of upper respiratory tract infection The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: a randomised controlled trial A multi-center, double-blind randomized study to assess the efficacy and tolerance of sulindac versus placebo in the symptomatic treatment of patients with upper respiratory tract infection Influence of loxoprofen use on recovery from naturally acquired upper respiratory tract infections: a randomized controlled trial Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study Meta-analysis of the effect of aspirin on mortality in COVID-19 Non-steroidal antiinflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study EMA gives advice on the use of non-steroidal antiinflammatories for COVID-19 Do NSAIDs worsen the outcomes in Acute Respiratory tract Infections (ARIs)?: The Centre for Evidence-Based Medicine Acute use of non-steroidal antiinflammatory drugs (NSAIDs) for people with or at risk of COVID-19: NHS England Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients Indomethacin"/syn OR "indomethacin*":ti,ab OR "diclofenac"/ syn OR "diclofenac":ti,ab OR "ibuprofen"/syn OR "ibuprofen*":ti,ab OR "acetylsalicylic acid"/syn OR "acetylsalicylic acid*":ti,ab OR "aspirin":ti,ab OR "naproxen"/syn or "naproxen*":ti,ab OR "ketorolac"/syn OR "ketorolac*":ti,ab) 2. ("Coronavirus infection"/syn OR "Coronavirus*":ti,ab OR "covid 19":ti,ab OR "respiratory tract infection"/syn OR "respiratory tract infection*":ti,ab OR "virus pneumonia"/syn OR "virus pneumonia":ti,ab OR "viral infection*":ti,ab OR "virus disease*":ti,ab OR "Coronaviridae"/syn OR "Coronavirid*":ti,ab OR "pneumonia"/syn OR Pneumonia*:ti,ab OR Pneumonitis*:ti,ab OR /syn OR "clinical study"/syn OR "controlled clinical trial"/syn OR "controlled clinical trial (topic) aspirin":ti,ab OR "naproxen"/syn or "naproxen*":ti,ab OR "ketorolac"/syn OR "ketorolac*":ti,ab) AND ("Coronavirus infection"/syn OR "Coronavirus*":ti,ab OR "covid 19":ti,ab OR "respiratory tract infection"/syn OR "respiratory tract infection*":ti,ab OR "virus pneumonia"/syn OR "virus pneumonia":ti,ab OR "viral infection*":ti,ab OR "virus disease*":ti,ab OR "Coronaviridae"/syn OR "Coronavirid*":ti,ab OR "pneumonia"/syn OR Pneumonia*:ti,ab OR Pneumonitis*:ti,ab OR "adult respiratory distress syndrome"/syn OR "respiratory distress syndrome":ti,ab OR "ARDS":ti,ab) AND ("clinical trial (topic)"/syn OR "clinical study"/syn OR "controlled clinical trial"/ syn OR "controlled clinical trial (topic)"/syn OR "randomized controlled trial (topic)"/syn OR Covid 19" OR "Respiratory Tract Infection*" OR "Viral Infection*" OR "Virus Disease*" OR Coronavirid* OR Pneumonia* OR Pneumonitis* OR "Respiratory Distress Syndrome Clinical Trial*" OR "Randomi?ed Controlled Trial*" OR "RCT" OR "Clinical Stud*" OR "Observation* Stud*" OR "In vitro #1 AND #2 AND #3 = AND (TITLE-ABS-KEY ( Coronavirus* OR "Covid 19" OR "Respiratory Tract Infection*" OR "Viral Infection*" OR "Virus Disease*" OR Coronavirid* OR Pneumonia* OR Pneumonitis* OR "Respiratory Distress Syndrome TS=(nonsteroid* antiinflammatory NEAR/3 agent*) OR Dichlofenal OR Diclinate OR Feloran OR Voltarol OR Novapirina OR Ortofen OR Orthofen OR Orthophen OR Voltaren OR Ibuprofen* OR Ibumetin OR Motrin OR Nuprin OR Rufen OR Salprofen OR Covid 19" OR "Respiratory Tract Infection*" OR "Viral Infection*" OR "Virus Disease Respiratory Distress Syndrome Clinical Trial*" OR "Randomi?ed Controlled Trial*" OR "RCT" OR "Clinical Stud*" OR "Observation* Stud*" OR "In vitro #1 AND #2 AND #3 = Dichlofenal OR Diclinate OR Feloran OR Voltarol OR Novapirina OR Ortofen OR Orthofen OR Orthophen OR Voltaren OR Ibuprofen* OR Ibumetin OR Motrin OR Nuprin OR Rufen OR Salprofen OR Respiratory Distress Syndrome Clinical Trial*" OR "Randomi?ed Controlled Trial*" OR "RCT" OR "Clinical Stud*" OR "Observation* Stud*" OR "In vitro COCHRANE LIBRARY 1. ([mh "Anti-Inflammatory Agents Acetylsalicylic Acid*":ti,ab OR COVID 19":ti,ab OR [mh "Respiratory Tract Infections"] OR "Respiratory Tract Infection*":ti,ab OR "Viral Infection*":ti,ab OR OR Pneumonia*:ti,ab OR Pneumonitis*:ti,ab OR Randomized Controlled Trials as Topic"] OR [mh "In Vitro Techniques"] OR "Clinical Trial":pt OR "Controlled Clinical Trial":pt OR "Randomized Controlled Trial":pt OR "Observational Study":pt OR "clinical trial*":ti,ab OR "controlled trial*":ti,ab OR Clinical Stud*:ti,ab OR "Observational Stud*":ti,ab OR "RCT":ti,ab OR #1 AND #2 AND #3 = 288 (281 Trial and 7 Cochrane Reviews) ([mh "Anti-Inflammatory Agents Acetylsalicylic Acid*":ti,ab OR OR Ketorolac*:ti,ab) AND ([mh "Coronavirus Infections"] OR Coronavirus*:ti,ab OR "COVID 19":ti,ab OR [mh "Respiratory Tract Infections"] OR "Respiratory Tract Infection*":ti,ab OR "Viral Infection*":ti,ab OR OR Pneumonia*:ti,ab OR Pneumonitis*:ti,ab OR Controlled Clinical Trial":pt OR "Randomized Controlled Trial":pt OR "Observational Study":pt OR "clinical trial*":ti,ab OR "controlled trial*":ti,ab OR Clinical Stud*:ti,ab OR "Observational Stud*":ti,ab OR "RCT":ti,ab OR Anti-Inflammatory Agents, Non-Steroidal OR Ibuprofen*[tiab] OR "Aspirin OR Acetylsalicylic Acid*[tiab] OR "Naproxen Coronavirus Infections OR Coronavirid*[tiab] OR "Pneumonia Randomized Controlled Trials as Topic Randomized Controlled Trial"[pt] OR "Observational Study OR in Vitro OR "diclofenac":ti,ab OR "ibuprofen"/syn OR "ibuprofen" OR "ibuprofen*":ti,ab OR "acetylsalicylic acid"/syn OR "acetylsalicylic acid" OR "acetylsalicylic acid*":ti,ab OR "aspirin":ti,ab OR "naproxen"/ syn OR "naproxen" OR "naproxen*":ti,ab OR "ketorolac"/syn OR "ketorolac" OR "ketorolac*":ti,ab) AND ("coronavirus infection"/syn OR "coronavirus infection" OR "coronavirus*":ti,ab OR "covid 19":ti,ab OR "respiratory tract infection"/syn OR "respiratory tract infection" OR "respiratory tract infection*":ti,ab OR "virus pneumonia"/ syn OR "virus pneumonia" OR "virus pneumonia":ti,ab OR "viral infection*":ti,ab OR OR "clinical study"/syn OR "clinical study" OR "controlled clinical trial"/syn OR "controlled clinical trial" OR "controlled clinical trial (topic) OR indomet*acin* OR osmosin OR indocid OR metindol OR amuno OR indocin OR diclo*enac* OR dicrofenac OR dichlofenal OR diclinate OR feloran OR voltarol OR novapirina OR ort*o*en OR voltaren OR ibuprofen* OR ibumetin OR motrin OR nuprin OR rufen OR "Salprofen OR Trauma Dolgit Gel" OR brufen OR aspirin OR acylpyrin OR aloxiprimum OR colfarit OR dispril OR easprin OR ecotrin OR endosprin OR magnecyl OR micristin OR polopirin OR polopiryna OR solprin OR solupsan OR zorprin OR acetysal OR acetylsalicylic AND acid* OR naproxen* OR methoxypropiocin OR anaprox OR Covid 19" OR "Respiratory Tract Infection*" OR "Viral Infection*" OR "Virus Disease*" OR coronavirid* OR pneumonia* OR pneumonitis* OR "Respiratory Distress Syndrome Covid 19" OR "Respiratory Tract Infection*" OR "Viral Infection*" OR "Virus Disease*" OR Coronavirid* OR Pneumonia* OR Pneumonitis* OR "Respiratory Distress Syndrome COCHRANE LIBRARY 1. #1 AND #2 AND #3 = 288 (281 Trials and 7 Cochrane Reviews) -521 (510 Trials and 11 Cochrane Reviews) ([mh "Anti-Inflammatory Agents Acetylsalicylic Acid*":ti,ab OR OR Ketorolac*:ti,ab) AND ([mh "Coronavirus Infections"] OR Coronavirus*:ti,ab OR "COVID 19":ti,ab OR [mh "Respiratory Tract Infections"] OR "Respiratory Tract Infection*":ti,ab OR "Viral Infection*":ti,ab OR OR Pneumonia*:ti,ab OR Pneumonitis*:ti,ab OR Controlled Clinical Trial":pt OR "Randomized Controlled Trial":pt OR "Observational Study":pt OR "clinical trial*":ti,ab OR "controlled trial*":ti,ab OR Clinical Stud*:ti,ab OR "Observational Stud*":ti,ab OR "RCT":ti,ab OR